Hepatitis A virus infection in Brazilian correctional facilities

Carregando...
Imagem de Miniatura
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
CASTRO, Lisie Souza
REZENDE, Grazielli Rocha de
PUGA, Marco Antonio Moreira
BANDEIRA, Larissa Melo
TANAKA, Tayana Serpa Ortiz
WEIS-TORRES, Sabrina
TAIRA, Deborah Ledesma
DEMARCHI, Luiz Henrique Ferraz
CRODA, Julio Rosa Henrique
Citação
PLOS ONE, v.18, n.4, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Hepatitis A virus (HAV) infection is transmitted by the fecal-oral route, through interpersonal contact and ingestion of contaminated food or water. Prisoners are at higher risk of acquiring HAV infection mainly due to the environment of closed penal institutions and socioeconomic conditions. This study aims to determine the seroprevalence of anti-HAV and its associated risk factors among inmates from twelve prisons in Central Brazil. A cross-sectional study was conducted between March 2013 and March 2014. A total of 580 prisoners participated in the study. The participant's samples were tested for Total and IgM anti-HAV antibodies by electrochemiluminescence immunoassay (ECLIA). Risk factors associated with anti-HAV seropositivity were also analyzed. The prevalence rate of HAV exposure was 88.1% (95% CI: 85.5-90.7). No sample had a positive reaction to IgM anti-HAV. Increasing age, low level of education, and being imprisoned in Corumba city were independently associated with HAV exposure among prisoners. To prevent the burden of the disease, vaccination strategies should be considered for susceptible prisoners in Central Brazil.
Palavras-chave
Referências
  1. [Anonymous], 2018, WPB WORLD PRIS BRIEF
  2. Bordi L, 2012, J CLIN VIROL, V54, P26, DOI 10.1016/j.jcv.2012.01.009
  3. Ximenes RAD, 2008, INT J EPIDEMIOL, V37, P852, DOI 10.1093/ije/dyn114
  4. Ximenes RAD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094622
  5. Souto FJD, 2019, VACCINE, V37, P771, DOI 10.1016/j.vaccine.2018.12.054
  6. El Maerrawi I, 2015, INT J STD AIDS, V26, P120, DOI 10.1177/0956462414531242
  7. Franco E, 2003, VACCINE, V21, P2224, DOI 10.1016/S0264-410X(03)00137-3
  8. Getaz L, 2016, INT J PRISON HEALTH, V12, P98, DOI 10.1108/IJPH-10-2015-0033
  9. Greco L, 2018, J MED VIROL, V90, P1323, DOI 10.1002/jmv.25052
  10. IBGE [database online], 2017, ESG SAN AD MIN PLAN
  11. Jacobsen KH, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031716
  12. Puga MAM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169195
  13. Rapicetta M, 2013, INFECTION, V41, P69, DOI 10.1007/s15010-012-0385-8
  14. Sequera VG, 2015, HUM VACC IMMUNOTHER, V11, P2615, DOI 10.1080/21645515.2015.1051269
  15. World Health Organization, 2017, GLOB HEP REP